$258M
Bispecific antibody Phase 2 deals command this upfront
Bispecific antibodies have emerged as a dominant force in immuno-oncology licensing. Their ability to engage multiple targets simultaneously creates compelling clinical differentiation, and deal terms reflect the breadth of potential indications and combination strategies.
Based on analysis of 600+ biopharma licensing deals from 2020-2026
Get deal intelligence in your inbox
Weekly benchmarks, market signals, and deal analysis from 1,900+ transactions.
No spam. Unsubscribe anytime.
Benchmarks powered by 1,900+ real biopharma licensing deals
Try the Deal Calculator →